2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
April 21st, 2025
Version: 2
The University of California, San Francisco
cancer biology
biorxiv

Human Papilloma Virus does not fully inactivate p53 cellular activity in HNSCC

Gencel-Augusto, J.Open in Google Scholar•Li, H.Open in Google Scholar•Woerner, L. C.Open in Google Scholar•Borah, A. A.Open in Google Scholar•Myers, J. N.Open in Google Scholar•Ha, P.Open in Google Scholar•Johnson, D. E.Open in Google Scholar•Grandis, J. R.Open in Google Scholar

Head and neck squamous cell carcinoma (HNSCC) is a major global health challenge. Inactivation of the tumor suppressor p53 is the most frequent molecular event in this malignancy. p53 inactivation occurs either through TP53 mutations in human papilloma virus (HPV)-negative cases or via HPV-mediated p53 degradation in HPV-positive (HPV+) cases, where most tumors retain a wild-type (WT) TP53 allele. This underscores the critical role of p53-regulated processes in HNSCC pathogenesis. Clinically, HPV+ HNSCC is associated with significantly better outcomes than HPV-negative cases. However, despite HPV E6-mediated degradation of p53, approximately 10% of HPV+ HNSCC tumors harbor TP53 mutations, suggesting an additional selective pressure to suppress p53 signaling. In this study, we demonstrate that HPV+ TP53-WT HNSCC cells have residual, tumor suppressive p53 activity. Specifically, analysis of human tumor data reveals that among HPV+ HNSCC cases, those with WT TP53 have significantly better survival outcomes than both HPV+ cases with TP53 mutations and HPV-negative cases. Experimentally, genetic ablation of WT p53 in HPV+ HNSCC cells increased proliferation, migration, and invasion. Transcriptomic analysis revealed that p53 continues to regulate gene expression despite the presence of HPV. Further, human tumors with HPV+ TP53-WT status exhibit tumor-suppressive methylation patterns, fewer chromosomal alterations, and suppression of PI3K-AKT signaling compared to HPV+ TP53-mutant tumors. Importantly, loss of WT p53 in HPV+ HNSCC cells increased the levels of PI3K catalytic subunit p110-alpha, reduced expression of the molecular PI3K-AKT inhibitor INPP5D and enhanced sensitivity to pharmacologic PI3K inhibition. Together, our findings challenge the prevailing view that p53 is completely inactivated in HPV+ HNSCC and reveal tumor suppressive, p53-driven mechanisms that persist in these tumors. These insights highlight a potential role for TP53-based stratification in guiding treatment decisions and suggest new therapeutic vulnerabilities in HPV+ HNSCC.

Similar Papers

biorxiv
Tue Apr 22 2025
Population analysis and immunologic landscape of melanoma in people living with HIV
People living with HIV (PLWH) diagnosed with melanoma have consistently exhibited worse clinical outcomes than HIV-negative individuals (PLw/oH) with the same cancer, even in the era of antiretroviral therapy (ART). To investigate the underlying factors contributing to these disparities, we analyzed electronic health records from 922 PLWH and 334,972 PLw/oH with melanoma. PLWH were diagnosed with ...
Barger, L. N.
•
Wang, D.
•
Saravia, A.
•
Mezzano, V.
...•
Romano, G.
biorxiv
Mon Apr 21 2025
A small molecule inhibitor of RNA-binding protein IGF2BP3 shows anti-leukemic activity
The RNA-binding protein IGF2BP3 is an oncofetal protein overexpressed in B-acute lymphoblastic leukemia and is critical for leukemogenesis in experimental models. With cancer-specific expression, functional dispensability for normal development, and an unleveraged pro-oncogenic function in mRNA homeostasis, IGF2BP3 represents an excellent target. With no small molecule inhibitors of IGF2BP3 in cli...
Jaiswal, A. K.
•
Scherer, G. M.
•
Thaxton, M. L.
•
Sorrentino, J. P.
...•
Rao, D. S.
biorxiv
Mon Apr 21 2025
The lnc-FANCI-2 intrinsically restricts RAS signaling in HPV16-infected cervical cancer
We recently discovered the expression of a long noncoding RNA, lnc-FANCI-2, coinciding with cervical lesion progression from CIN1, CIN2-3 to cervical cancer. Viral E7 of high-risk HPVs and host transcription factor YY1 are two major factors promoting lnc-FANCI-2 expression. To explore possible roles of lnc-FANCI-2 in HPV-induced cervical carcinogenesis, we ablated the expression of lnc-FANCI-2 in ...
Liu, H.
•
Yu, L.
•
Majerciak, V.
•
Meyer, T.
...•
Zheng, Z.-M.
biorxiv
Mon Apr 21 2025
Single-Cell Pharmacogenomic Landscapes of Epigenetic Therapy in Gastric Cancer
Gene expression signatures (\"molecular phenotypes\") are extensively utilized in cancer research. Using direct capture Perturb-seq (dcPerturb-seq), we surveyed how molecular phenotypes in gastric cancer (GC) are shaped by cell-intrinsic genetic alterations interacting with cell-extrinsic therapeutic exposures. Interrogating >200 GC-related genes against 4 distinct epigenetic drug classes across m...
Xu, C.
•
Ma, H.
•
Sheng, T.
•
Lee, M. H.
...•
Tan, P.
biorxiv
Mon Apr 21 2025
NOX4 prevents the recruitment of PAX8 and NKX2.1 to chromatin in BRAF-mutated thyroid cancer cells.
Radioiodine (RAI) therapy, used for treating thyroid cancers, hinges on the expression of the Sodium Iodide Symporter (NIS). The majority of differentiated thyroid cancers (DTCs) are papillary, with a BRAFV600E mutation. This mutation correlates with an absence of RAI uptake, due to low NIS expression and a low differentiation score. NADPH oxidase 4 (NOX4)-derived ROS contribute to NIS repression ...
Radom, M.
•
Buffet, C.
•
Cazarin, J.
•
Harinquet, M.
...•
DUPUY, C.
biorxiv
Mon Apr 21 2025
Phosphoproteomics Uncovers Tumor Heterogeneity and Therapeutic Opportunities in Early-Stage Hepatocellular Carcinoma
Background and Aims: Hepatocellular carcinoma (HCC) is a highly heterogeneous cancer, with mechanisms of initiation, progression, and recurrence not fully clarified. While prior large-scale phosphoproteomic studies in HCC have mapped phosphorylation dynamics and identified subgroups consistent with proteomic subgroups, the role of phosphorylation in early-stage HCC heterogeneity and therapeutic vu...
Ren, L.
•
Jiang, J.
•
Lin, W.
•
Qi, L.
...•
Jiang, Y.
biorxiv
Mon Apr 21 2025
The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high MYC malignancies.
Ribosome biogenesis (RiBi) is a key determinant of cell growth and proliferation and is highly elevated in cancer due to the activation by oncogenes such as MYC. First-generation RiBi inhibitor CX-5461, while demonstrating clinical potential for cancer treatment, also induces DNA damage through off-target inhibition of TOP2 and potentially other mechanisms, bringing into question RiBi as a target ...
Ferreira, R.
•
Hannan, K. M.
•
Panov, K.
•
Udumanne, T.
...•
Hein, N.
biorxiv
Fri Apr 18 2025
New Δ246p53 isoform responds to DNA damage to enhance p53 functions in senescence and tumour suppression
p53 is with little doubt one of the most powerful genes in our genome, as it makes growth vs arrest, repair vs replacement, metabolism vs anabolism, life vs death decisions in the cell. An alteration or malfunction in p53 may lead to cancer or premature ageing. So, it is not surprising that p53 is also one of the most complex and tightly regulated genes. p53 alone encodes for at least 10 RNA varia...
Parkar, S. N.
•
Ramalho, A. C.
•
Lopez-Iniesta, M. J.
•
Kimura, K.
...•
Candeias, M. M.
biorxiv
Fri Apr 18 2025
Transcriptional regulators FOXD1 and RBFOX2 contribute to metastatic capacity in BAP1mut uveal melanoma
Uveal melanoma is the most prevalent primary intraocular cancer, with a significant metastatic risk. This risk is dependent on the genetic drivers. Secondary mutations in EIF1AX, SF3B1 and BAP1 correlate with clinical outcomes and are recognized for their distinct transcriptomic and epigenetic profiles. Previously, we identified 480 genes involved in the development of ocular melanocytes. Top rank...
Brosens, E.
•
Nguyen, J.
•
Konemann, N.
•
van den Bosch, T.
...•
van den Bosch, Q.